NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

March 4, 2026 - 01:18

NeuroPace, Inc., a leader in developing responsive neurostimulation for epilepsy, has announced its financial results for the fourth quarter and full year ending December 31, 2025. The company also reaffirmed its financial and operational outlook for the ongoing 2026 fiscal year.

The reported figures indicate a year of significant growth. Full-year revenue for 2025 reached $84.5 million, marking a substantial 27% increase compared to the previous year. This growth was driven by a consistent rise in the adoption of the company's RNS System. The fourth quarter alone contributed $22.8 million in revenue, demonstrating sustained commercial momentum.

Operationally, NeuroPace highlighted several key achievements from 2025, including the continued enrollment in its landmark NAUTILUS study, which is investigating the use of its technology for idiopathic generalized epilepsy. The company also emphasized its ongoing efforts to expand clinical evidence and enhance physician training programs to support broader patient access.

Looking forward, management expressed confidence by reiterating its previously provided 2026 revenue guidance. The company's leadership stated that the strong finish to 2025 provides a solid foundation for continued execution on strategic initiatives aimed at addressing the large unmet needs within the epilepsy community. The focus remains on driving awareness and improving the standard of care for patients with drug-resistant epilepsy through its innovative platform.